We're a Registered Charity Organization in Tanzania
Ifakara Health Institute (IHI) is officially recognized as a charitable organization under the Income Tax Act.
Certification issued on 20 March 2025 and valid until 31 December 2030.
@70Principal Investigator: Dr. Yeromin Mlacha
Project leader/ Coordinator: Dr. Yeromin Mlacha
Project Administrator: Felix Brown
Funding Partner: Novo Nordisk Foundation through the Royal Danish Academy for Fine Arts
Start date: Jan. 1, 2022
End date: Dec. 31, 2026
This project aims to assess the risk of mosquito-borne diseases in Dar es Salaam, based on deep learning and remote sensing.
By assessing the risk of vector-borne diseases, the project will enhance knowledge of the relationship between the physical environment and mosquito-borne diseases and develop tools to identify risk areas of mosquito-borne diseases in Eastern African cities. This will eventually guide policy and interventions that will enhance livelihoods based on multi-scale data from the individual household level to the metropolitan level.
The project will apply the research methods below:
Mosquito densities, socioeconomic conditions, and housing conditions of 25 randomly selected households in each sample area will be surveyed. At baseline, households will be provided with long-lasting insecticidal nets. Mosquito densities will be surveyed weekly in each house for 24 months with: i) CDC light trap (CDC-LT) collections; ii) Mosquito resting collections; iii) Human baited double net (HND) collections and; iv) Larval collections.
The proposed study location is Dar es Salaam. Specific study sites are yet to be selected.
The project will be subdivided into four phases, spanning over 5 years from January 2022 to December 2026.
The study will be a collaborative project involving a team from:
The direction of the project will be undertaken by the principal investigator, Jakob Brandtberg Knudsen, Dean of Architecture at RDA. The deep learning research will be overseen by Christian Igel, a professor at DIKU. The remote sensing research will be overseen by Rasmus Fensholt, a professor at IGN.
The epidemiological research will be overseen by Fredros Okumu, the Director of Science at IHI, and James Logan, professor at the Department of Disease Control, LSHTM.
This project is funded by the Novo Nordisk Foundation through the Royal Danish Academy for Fine Arts.